Construction of a Novel Gene Transfection System with Dextran-Spermine as the Non-Viral Vector
WANG Gang1，LI Qing-yu1，SUN Guo-ming1， HE Cai-xia2， ZHU Xiu-mei2， XU Jian-feng3， GAO Jian-qing2*
Author information+
1.Department of Pharmacy， First People's Hospital of Hangzhou， Hangzhou 310006， China; 2.Institute of Pharmaceutics， College of Pharmaceutical Sciences， Zhejiang University， Hangzhou 310058， China; 3.Zhejiang Dingtai Pharmaceutical Co.， LTD， Tongxiang 314500， China
ABSTRACT: OBJECTIVE To evaluate the transfection effect of dextran-spermine and to develop a novel gene delivery system. METHODS Dextran-spermine was complexed with the plasmid DNA coding for luciferase， then the particle size and Zeta potentials of the nanoparticles were investigated. Dextran-spermine /pDNA complexes were used to transfect tumor cells and mesenchymal stem cells either in the presence or absence of serum. Anionized gelatin was synthesized and used to construct reverse transfection system. Gene expression with reverse transfection method was compared with the conventional transfection method. RESULTS Dextran-spermine /pDNA complexes can effectively transfect cells. In contrast to the conventional transfection method， the reverse transfection method permitted the transfection of cells in the presence of serum. CONCLUSION Dextran-spermine is a promising gene carrier. The reverse transfection system has reduced the negative influence of serum， and will be a promising gene delivery method.
WNG Gng;LI Qing-yu;SUN Guo-ming;HE Ci-xi;ZHU Xiu-mei;XU Jin-feng;GO Jin-qing.
Construction of a Novel Gene Transfection System with Dextran-Spermine as the Non-Viral Vector[J]. Chinese Pharmaceutical Journal, 2011, 46(10): 757-760
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] BOULAIZ H， MARCHAL J A， PRADOS J， et al. Non-viral and viral vectors for gene therapy [J]. Cell Mol Biol， 2005， 51(1: 3-22. [2] ST G J. Gene therapy progress and prospects: adenoviral vectors[J]. Gene Ther， 2003， 10(14: 1135-1141. [3] LI S D， HUANG L. Non-viral is superior to viral gene delivery [J]. J Controlled Release， 2007， 123(3: 181-183. [4] HOSSEINKHANI H， AZZAM T， TABATA Y， et al. Dextran-spermine polycation: an efficient nonviral vector for in vitro and in vivo gene transfection[J]. Gene Ther， 2004， 11(2: 194-203. [5] JO J， NAGAYA N， MIYAHARA Y， et al. Transplantation of genetically engineered mesenchymal stem cells improves cardiac function in rats with myocardial infarction: benefit of a novel nonviral vector， cationized dextran [J]. Tissue Eng， 2007， 13(2: 313-322. [6] DE LAPORTE L， SHEA L D. Matrices and scaffolds for DNA delivery in tissue engineering[J]. Adv Drug Deliv Rev， 2007， 59(4-5: 292-307. [7] UCHIMURA E， YAMADA S， NOMURA T，et al. Reverse transfection using antibodies against a cell surface antigen in mammalian adherent cell lines[J]. J Biosci Bioeng， 2007， 104(2: 152-155. [8] HE C X， TABATA Y， GAO J Q. Non-viral gene delivery carrier and its three-dimensional transfection system [J]. Int J Pharm， 2010， 386(1-2: 232-242. [9] OKAZAKI A， JO J， TABATA Y. A reverse transfection technology to genetically engineer adult stem cells[J]. Tissue Eng， 2007， 13(2: 245-251. [10] POTIER E， FERREIRA E， MEUNIER A， et al. Prolonged hypoxia concomitant with serum deprivation induces massive human mesenchymal stem cell death[J]. Tissue Eng， 2007， 13(6: 1325-1331. [11] LECHARDEUR D， VERKMAN A S， LUKACS G L. Intracellular routing of plasmid DNA during non-viral gene transfer[J]. Adv Drug Deliv Rev， 2005， 57(5: 755-767.
PDF(1181 KB)
